Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, MURPHY ANDREW J, holds the title of Co-Chief Scientific Officer at REGENERON PHARMACEUTICALS, INC..
On 2026-11-16, the insider transacted 34,000 shares.The shares were transacted at a weighted average price of $670.64 per share, resulting in a total market-relevant value of $22.8M.
MURPHY ANDREW J (Co-Chief Scientific Officer) had withheld for taxes $22.8M of $REGN
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.